Skip to main content
. 2023 Oct 24;23:1030. doi: 10.1186/s12885-023-11543-5

Table 3.

Clinic and transplant characteristics in Allogeneic hematopoietic stem cell transplantation patients

Characteristic Low PLT (≤ 65 × 109/L) group (n = 127) High PLT (> 65 × 109/L) group (n = 50) P value
Median patients age (range) 39 (17–65) 38 (18–61) 0.725
Gender, n (%) 0.318
Male 58 (45.7) 27 (54.0)
Female 69 (54.3) 23 (46.0)
Type of donor, n (%) 0.892
MSD 53 (41.7) 19 (38.0)
HID 72 (56.7) 30 (60.0)
MUD 2 (1.6) 1 (2.0)
Stem cell source, n (%) 0.219
PBSC 48 (37.8) 14 (28.0)
PBSC + BM 79 (62.2) 36 (72.0)
Conditioning regimen, n (%) 0.212
Bu-Cy 91 (71.6) 31 (62.0)
Bu-Flu 36 (28.4) 19 (38.0)
GVHD prophylaxis, n (%) 0.863
CsA + MTX 53 (41.7) 19 (38.0)
CsA + MTX + ATG 6 (4.7) 2 (4.0)
CsA + MTX + ATG + MMF 68 (53.6) 29 (58.0)

MSD HLA-matched sibling donor, MUD HLA-matched unrelated donor, HID haploidentical related donors, PBSC peripheral blood stem cell, BM bone morrow, Bu busulfan, Cy cyclophosphamide, Flu fludarabine, GVHD graft-versus-host disease, CsA cyclosporine A, MTX methotrexate, ATG antithymocyte globulin, MMF mycophenolate